CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞瞄准新靶点：增强 B 细胞来源恶性肿瘤过继细胞治疗的新方法
英文原题：CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies.
查看英文原题
CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T 细胞疗法无疑是对抗多种血液系统恶性肿瘤的有前景工具。然而，该疗法尚不完善，相当一部分患者无应答或治疗后复发。要改进治疗，需仔细分析现存问题并深入理解其原因。本文总结 CAR-T 产品临床表现的最新认识，并讨论为改善该疗法主要缺点而采取的多种策略。我们尤其关注 CD19 CAR-T 治疗 B 细胞来源恶性肿瘤所面临的挑战，并回顾介导治疗耐药机制的最新发现。由于 CD19 丢失是 CAR-T 治疗成功的主要障碍之一，本文介绍可替代用于治疗不同类型 B 细胞来源癌症的抗原。
展开英文摘要原文
Chimeric antigen receptor (CAR)-T cell therapy is undeniably a promising tool in combating various types of hematological malignancies.
However, it is not yet optimal and a significant number of patients experience a lack of response or relapse after the treatment. Therapy improvement requires careful analysis of the occurring problems and a deeper understanding of the reasons that stand behind them. In this review, we summarize the recent knowledge about CAR-T products' clinical performance and discuss diversified approaches taken to improve the major shortcomings of this therapy.
Especially, we prioritize the challenges faced by CD19 CAR-T cell-based treatment of B cell-derived malignancies and revise the latest insights about mechanisms mediating therapy resistance. Since the loss of CD19 is one of the major obstacles to the success of CAR-T cell therapy, we present antigens that could be alternatively used for the treatment of various types of B cell-derived cancers.
论文信息
- 作者
- Marhelava K、Krawczyk M、Firczuk M、Fidyt K
- 单位
- Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland.Poland
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Cells2022 May 31
- 原文标识
- PubMed 35681499 · DOI 10.3390/cells11111804
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →